Abstract 382P
Background
Much of the inter-individual differences in the regulation, expression, and activity of drug metabolizing enzymes genes might be crucial factors in defining cancer susceptibility, as well as in determining the efficacy of drugs. Cytochrome P450 (CYP) family of enzymes are the most important drug metabolizing enzymes involved in the metabolism of widely used drugs including anticancer drugs like tamoxifen and cyclophosphamide. Therefore, present study was undertaken to investigate the association of variant genotypes of CYP2C9, CYP2C19 & CYP2D6 with the treatment response (personalized medicine approach) in Head and Neck cancer cases receiving chemotherapy or combination of chemo- and radiotherapy.
Methods
800 patients suffering from Head & Neck cancer and equal number of age matched controls were included in the study. Genomic DNA was isolated from the blood samples and CYP2C9, CYP2C19 & CYP2D6 genotypes were determined in genomic DNA by PCR based RFLP. Follow-up carried out to correlate the association (if any) in between variants and treatment outcome.
Results
Amongst heterozygous and homozygous variants of CYP2C9*2/*3; CYP2C19*2 /*3 (i.e. CYP2C9*1/*2, CYP2C9*1/*3, CYP2C19*1/*2 & CYP2C19*1/*3) and CYP2D6*4/*10, a high percentage of cases was encountered as non-responders and had toxicities like nausea, vomiting, dizziness etc., as compared to the responders in the same category. In the follow-up study, it was found that a significantly higher number of non-responders (p-value<0.05) were encountered in the cases carrying variant genotypes of either of CYP2C9*2, CYP2C9*3, CYP2C9*2/*3, CYP2C19*2, CYP2C19*3, CYP2C19*2/*3, CYP2D6*4 and CYP2D6*10.
Conclusions
It was demonstrated that CYP2C9, CYP2C19 and CYP2D6 variants modify the treatment outcome in cases receiving combination of radio-chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Government of India.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract